- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.85 Å
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-6)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- FUC: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN-MAN-FUC.2: 6 residues within 4Å:- Chain A: Q.74, N.75, E.113, F.114, I.115, R.144
1 PLIP interactions:1 interactions with chain A- Hydrophobic interactions: A:N.75
NAG-NAG-BMA-MAN-MAN-FUC.17: 6 residues within 4Å:- Chain E: Q.74, N.75, E.113, F.114, I.115, R.144
1 PLIP interactions:1 interactions with chain E- Hydrophobic interactions: E:N.75
NAG-NAG-BMA-MAN-MAN-FUC.32: 6 residues within 4Å:- Chain I: Q.74, N.75, E.113, F.114, I.115, R.144
1 PLIP interactions:1 interactions with chain I- Hydrophobic interactions: I:N.75
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-MAN.3: 9 residues within 4Å:- Chain A: V.157, N.159, T.161, V.236, V.238, N.240
- Chain I: S.213, P.215, W.216
4 PLIP interactions:2 interactions with chain A, 2 interactions with chain I- Hydrophobic interactions: A:V.236, A:V.238, I:P.215
- Hydrogen bonds: I:W.216
NAG-NAG-BMA-MAN.18: 9 residues within 4Å:- Chain A: S.213, P.215, W.216
- Chain E: V.157, N.159, T.161, V.236, V.238, N.240
4 PLIP interactions:2 interactions with chain E, 2 interactions with chain A- Hydrophobic interactions: E:V.236, E:V.238, A:P.215
- Hydrogen bonds: A:W.216
NAG-NAG-BMA-MAN.33: 9 residues within 4Å:- Chain E: S.213, P.215, W.216
- Chain I: V.157, N.159, T.161, V.236, V.238, N.240
4 PLIP interactions:2 interactions with chain I, 2 interactions with chain E- Hydrophobic interactions: I:V.236, I:V.238, E:P.215
- Hydrogen bonds: E:W.216
- 3 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
NAG-NAG.4: 8 residues within 4Å:- Chain A: S.39, S.40, P.278, N.279, V.291, N.292, K.293
- Chain B: E.69
No protein-ligand interaction detected (PLIP)NAG-NAG.19: 8 residues within 4Å:- Chain E: S.39, S.40, P.278, N.279, V.291, N.292, K.293
- Chain F: E.69
No protein-ligand interaction detected (PLIP)NAG-NAG.34: 8 residues within 4Å:- Chain I: S.39, S.40, P.278, N.279, V.291, N.292, K.293
- Chain J: E.69
No protein-ligand interaction detected (PLIP)- 3 x NAG- NAG- BMA- FUC: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
NAG-NAG-BMA-FUC.5: 8 residues within 4Å:- Chain B: N.146, A.147, E.150, S.151, N.154, T.156
- Chain D: S.31, M.32
1 PLIP interactions:1 interactions with chain D- Hydrogen bonds: D:M.32
NAG-NAG-BMA-FUC.20: 8 residues within 4Å:- Chain F: N.146, A.147, E.150, S.151, N.154, T.156
- Chain H: S.31, M.32
1 PLIP interactions:1 interactions with chain H- Hydrogen bonds: H:M.32
NAG-NAG-BMA-FUC.35: 8 residues within 4Å:- Chain J: N.146, A.147, E.150, S.151, N.154, T.156
- Chain L: S.31, M.32
1 PLIP interactions:1 interactions with chain L- Hydrogen bonds: L:M.32
- 30 x SO4: SULFATE ION(Non-functional Binders)
SO4.6: 4 residues within 4Å:- Chain A: I.28, R.315
- Chain B: G.1, A.7
Ligand excluded by PLIPSO4.7: 5 residues within 4Å:- Chain A: A.298
- Chain B: K.58, T.59, N.60, K.62
Ligand excluded by PLIPSO4.8: 5 residues within 4Å:- Chain B: R.127, H.159, D.160
- Chain J: M.133, K.139
Ligand excluded by PLIPSO4.9: 3 residues within 4Å:- Chain B: K.39, K.121, G.155
Ligand excluded by PLIPSO4.10: 3 residues within 4Å:- Chain D: S.54, R.55, R.56
Ligand excluded by PLIPSO4.11: 4 residues within 4Å:- Chain D: P.61, D.62, R.63, R.79
Ligand excluded by PLIPSO4.12: 3 residues within 4Å:- Chain D: S.54, R.56, S.65
Ligand excluded by PLIPSO4.13: 3 residues within 4Å:- Chain D: P.61, R.63, A.83
Ligand excluded by PLIPSO4.14: 2 residues within 4Å:- Chain D: K.192, R.213
Ligand excluded by PLIPSO4.15: 3 residues within 4Å:- Chain D: K.41, Q.44, R.47
Ligand excluded by PLIPSO4.21: 4 residues within 4Å:- Chain E: I.28, R.315
- Chain F: G.1, A.7
Ligand excluded by PLIPSO4.22: 5 residues within 4Å:- Chain E: A.298
- Chain F: K.58, T.59, N.60, K.62
Ligand excluded by PLIPSO4.23: 5 residues within 4Å:- Chain B: M.133, K.139
- Chain F: R.127, H.159, D.160
Ligand excluded by PLIPSO4.24: 3 residues within 4Å:- Chain F: K.39, K.121, G.155
Ligand excluded by PLIPSO4.25: 3 residues within 4Å:- Chain H: S.54, R.55, R.56
Ligand excluded by PLIPSO4.26: 4 residues within 4Å:- Chain H: P.61, D.62, R.63, R.79
Ligand excluded by PLIPSO4.27: 3 residues within 4Å:- Chain H: S.54, R.56, S.65
Ligand excluded by PLIPSO4.28: 3 residues within 4Å:- Chain H: P.61, R.63, A.83
Ligand excluded by PLIPSO4.29: 2 residues within 4Å:- Chain H: K.192, R.213
Ligand excluded by PLIPSO4.30: 3 residues within 4Å:- Chain H: K.41, Q.44, R.47
Ligand excluded by PLIPSO4.36: 4 residues within 4Å:- Chain I: I.28, R.315
- Chain J: G.1, A.7
Ligand excluded by PLIPSO4.37: 5 residues within 4Å:- Chain I: A.298
- Chain J: K.58, T.59, N.60, K.62
Ligand excluded by PLIPSO4.38: 5 residues within 4Å:- Chain F: M.133, K.139
- Chain J: R.127, H.159, D.160
Ligand excluded by PLIPSO4.39: 3 residues within 4Å:- Chain J: K.39, K.121, G.155
Ligand excluded by PLIPSO4.40: 3 residues within 4Å:- Chain L: S.54, R.55, R.56
Ligand excluded by PLIPSO4.41: 4 residues within 4Å:- Chain L: P.61, D.62, R.63, R.79
Ligand excluded by PLIPSO4.42: 3 residues within 4Å:- Chain L: S.54, R.56, S.65
Ligand excluded by PLIPSO4.43: 3 residues within 4Å:- Chain L: P.61, R.63, A.83
Ligand excluded by PLIPSO4.44: 2 residues within 4Å:- Chain L: K.192, R.213
Ligand excluded by PLIPSO4.45: 3 residues within 4Å:- Chain L: K.41, Q.44, R.47
Ligand excluded by PLIP- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Ekiert, D.C. et al., A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011)
- Release Date
- 2011-07-20
- Peptides
- Hemagglutinin HA1 chain: AEI
Hemagglutinin HA2 chain: BFJ
Antibody CR8020, Heavy Chain: CGK
Antibody CR8020, Light Chain: DHL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
AI
AB
BF
BJ
BC
HG
HK
HD
LH
LL
L
- Coordinates
- PDB Format
- Method
- X-RAY DIFFRACTION 2.85 Å
- Oligo State
- hetero-3-3-3-3-mer
- Ligands
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-6)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN- MAN- FUC: alpha-D-mannopyranose-(1-3)-[alpha-D-mannopyranose-(1-6)]beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG- BMA- MAN: alpha-D-mannopyranose-(1-3)-beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose
- 3 x NAG- NAG: 2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose(Post Translational Modification)
- 3 x NAG- NAG- BMA- FUC: beta-D-mannopyranose-(1-4)-2-acetamido-2-deoxy-beta-D-glucopyranose-(1-4)-[alpha-L-fucopyranose-(1-6)]2-acetamido-2-deoxy-beta-D-glucopyranose
- 30 x SO4: SULFATE ION(Non-functional Binders)
- Links
- RCSB PDBe PDBe-KB PDBj PDBsum CATH PLIP
- Citation
- Ekiert, D.C. et al., A highly conserved neutralizing epitope on group 2 influenza A viruses. Science (2011)
- Release Date
- 2011-07-20
- Peptides
- Hemagglutinin HA1 chain: AEI
Hemagglutinin HA2 chain: BFJ
Antibody CR8020, Heavy Chain: CGK
Antibody CR8020, Light Chain: DHL - SMTL:PDB
- SMTL Chain Id:
PDB Chain Id:A
AE
AI
AB
BF
BJ
BC
HG
HK
HD
LH
LL
L